Margareta Puu

1.6k total citations
18 papers, 1.1k citations indexed

About

Margareta Puu is a scholar working on Pulmonary and Respiratory Medicine, Physiology and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Margareta Puu has authored 18 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Pulmonary and Respiratory Medicine, 10 papers in Physiology and 4 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Margareta Puu's work include Asthma and respiratory diseases (10 papers), Respiratory and Cough-Related Research (6 papers) and Heart Failure Treatment and Management (4 papers). Margareta Puu is often cited by papers focused on Asthma and respiratory diseases (10 papers), Respiratory and Cough-Related Research (6 papers) and Heart Failure Treatment and Management (4 papers). Margareta Puu collaborates with scholars based in Sweden, United Kingdom and Canada. Margareta Puu's co-authors include Salim Yusuf, John J.V. McMurray, Eric L. Michelson, Karl Swedberg, Christopher B. Granger, Marc A. Pfeffer, Anique Ducharme, Lars Olsson, Bengt Larsson and Paul M. O’Byrne and has published in prestigious journals such as Journal of the American College of Cardiology, European Heart Journal and European Respiratory Journal.

In The Last Decade

Margareta Puu

17 papers receiving 1.1k citations

Peers

Margareta Puu
Xavier Jaumont Switzerland
Giuseppe Di Tano Italy
Seongwoo Han South Korea
Bente Krogsgaard Schaadt Denmark
Eirik Ikdahl Norway
Gökhan Aksan Türkiye
Giosafat Spitaleri Spain
Vicente Ruíz Spain
Serkan Yüksel Türkiye
Amit Nautiyal United States
Xavier Jaumont Switzerland
Margareta Puu
Citations per year, relative to Margareta Puu Margareta Puu (= 1×) peers Xavier Jaumont

Countries citing papers authored by Margareta Puu

Since Specialization
Citations

This map shows the geographic impact of Margareta Puu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Margareta Puu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Margareta Puu more than expected).

Fields of papers citing papers by Margareta Puu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Margareta Puu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Margareta Puu. The network helps show where Margareta Puu may publish in the future.

Co-authorship network of co-authors of Margareta Puu

This figure shows the co-authorship network connecting the top 25 collaborators of Margareta Puu. A scholar is included among the top collaborators of Margareta Puu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Margareta Puu. Margareta Puu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Reddel, Helen K., Paul M. O’Byrne, J. Mark FitzGerald, et al.. (2021). Efficacy and Safety of As-Needed Budesonide-Formoterol in Adolescents with Mild Asthma. The Journal of Allergy and Clinical Immunology In Practice. 9(8). 3069–3077.e6. 18 indexed citations
2.
FitzGerald, J. Mark, Paul M. O’Byrne, Eric D. Bateman, et al.. (2021). Safety of As-Needed Budesonide-Formoterol in Mild Asthma: Data from the Two Phase III SYGMA Studies. Drug Safety. 44(4). 467–478. 12 indexed citations
3.
O’Byrne, Paul M., J. Mark FitzGerald, Eric D. Bateman, et al.. (2020). Effect of a single day of increased as-needed budesonide–formoterol use on short-term risk of severe exacerbations in patients with mild asthma: a post-hoc analysis of the SYGMA 1 study. The Lancet Respiratory Medicine. 9(2). 149–158. 41 indexed citations
4.
Fitzgerald, Mark, Paul M. O’Byrne, Eric D. Bateman, et al.. (2019). Number needed to treat (NNT) to have an additional patient free from a severe or moderate/severe exacerbation: post-hoc analysis of SYGMA 1 in mild asthma. PA3716–PA3716. 2 indexed citations
5.
O’Byrne, Paul M., Eric D. Bateman, J. Mark FitzGerald, et al.. (2019). Efficacy of As-Needed Budesonide/Formoterol for Reducing Severe Exacerbations in Adolescents with Mild Asthma: Pooled Subgroup Analysis of the SYGMA 1 and 2 Trials. A7191–A7191. 1 indexed citations
6.
Reddel, Helen K., Eric D. Bateman, J. Mark FitzGerald, et al.. (2019). Exacerbation risk after night-time waking due to asthma in SYGMA 1. PA3715–PA3715. 2 indexed citations
7.
O’Byrne, Paul M., J. Mark FitzGerald, Eric D. Bateman, et al.. (2019). Risk of a severe exacerbation following higher reliever use: post-hoc analysis of SYGMA 1 in mild asthma. Pneumologie. 2 indexed citations
8.
O’Byrne, Paul M., J. Mark FitzGerald, Eric D. Bateman, et al.. (2018). Late Breaking Abstract - Risk of a severe exacerbation following higher reliever use: post-hoc analysis of SYGMA 1 in mild asthma. OA1680–OA1680. 1 indexed citations
9.
Pearlman, David S., Julie McLaren, Rosa Lamarca, et al.. (2017). Efficacy and safety of budesonide/formoterol pMDI vs budesonide pMDI in asthmatic children (6–<12 years). Annals of Allergy Asthma & Immunology. 118(4). 489–499.e1. 12 indexed citations
10.
O’Byrne, Paul M., Hristo Metev, Margareta Puu, et al.. (2016). Efficacy and safety of a CXCR2 antagonist, AZD5069, in patients with uncontrolled persistent asthma: a randomised, double-blind, placebo-controlled trial. The Lancet Respiratory Medicine. 4(10). 797–806. 196 indexed citations
11.
Soyza, Anthony De, Ian Pavord, J.S. Elborn, et al.. (2015). A randomised, placebo-controlled study of the CXCR2 antagonist AZD5069 in bronchiectasis. European Respiratory Journal. 46(4). 1021–1032. 76 indexed citations
12.
Pavord, Ian, Anthony De Soyza, J.S. Elborn, et al.. (2013). Efficacy and safety of AZD5069, a CXCR2 antagonist, in adult bronchiectasis. European Respiratory Journal. 42(Suppl 57). P1593–P1593. 7 indexed citations
13.
14.
Meredith, Peter, Jan Östergren, Inder S. Anand, et al.. (2008). Clinical Outcomes According to Baseline Blood Pressure in Patients With a Low Ejection Fraction in the CHARM (Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity) Program. Journal of the American College of Cardiology. 52(24). 2000–2007. 33 indexed citations
15.
Cohen‐Solal, Alain, John J.V. McMurray, K. Swedberg, et al.. (2008). Benefits and safety of candesartan treatment in heart failure are independent of age: insights from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity programme. European Heart Journal. 29(24). 3022–3028. 32 indexed citations
16.
Olsson, Lars, Karl Swedberg, Anique Ducharme, et al.. (2006). Atrial Fibrillation and Risk of Clinical Events in Chronic Heart Failure With and Without Left Ventricular Systolic Dysfunction. Journal of the American College of Cardiology. 47(10). 1997–2004. 425 indexed citations
17.
18.
Puu, Margareta. (2003). Optimum Experimental Designs for Generalized Linear Models with Multinomial Response.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Xavier Jaumont Breakdown of academic impact, for papers by Giuseppe Di Tano Breakdown of academic impact, for papers by Seongwoo Han Breakdown of academic impact, for papers by Bente Krogsgaard Schaadt Breakdown of academic impact, for papers by Eirik Ikdahl Breakdown of academic impact, for papers by Gökhan Aksan Breakdown of academic impact, for papers by Giosafat Spitaleri Breakdown of academic impact, for papers by Vicente Ruíz Breakdown of academic impact, for papers by Serkan Yüksel Breakdown of academic impact, for papers by Amit Nautiyal
Rankless by CCL
2026